Granisetron Hydrochloride and Glucose Injection

Pharmacological action: This product is a highly selective 5HT3 receptor antagonist, which has a good preventive and therapeutic effect on nausea and vomiting caused by radiotherapy, chemotherapy and surgery. Factors such as radiotherapy, chemotherapy and surgical operations can cause enterochromaffin cells to release 5HT, and 5HT can activate the 5HT3 receptors of the central nervous system or vagus nerve to cause vomiting reflex. The mechanism of this product in controlling nausea and vomiting is to antagonize the 5HT3 receptors in the central chemoreceptor area and peripheral vagus nerve endings, thereby inhibiting the occurrence of nausea and vomiting. This product has high selectivity and no side effects such as extrapyramidal reactions and excessive sedation. Toxicological studies Reproductive toxicity: When the subcutaneous dose of this product reaches 6 mg/kg/day (based on body surface area, it is 97 times the recommended dose for clinical intravenous administration),

Granisetron Hydrochloride

Used for nausea and vomiting caused by radiotherapy and cytotoxic chemotherapy.

Intravenous drip, the recommended dosage for adults is usually 3 mg, administered 30 minutes before chemotherapy. Most patients only need to take the drug once, and the prevention effect on nausea and vomiting can last for more than 24 hours. If necessary, the frequency of administration can be increased by 1 to 2 times, but the maximum daily dose should not exceed 9 mg. The elderly and patients with liver and kidney dysfunction do not need to adjust the dosage. The infusion time should be no less than 5 minutes.

Common side effects include headache, fatigue, fever, constipation, and occasional transient asymptomatic increase in liver transaminases. These reactions are mild and can be recovered without special treatment.

1. Patients with intestinal obstruction are prohibited from using this product. 2. Patients who are allergic to this product are prohibited from using this product.

1 Granisetron is metabolized by the hepatic cytochrome P-450 drug metabolizing enzyme system. Inducing or inhibiting this enzyme can change the clearance rate and half-life of granisetron. 2 Granisetron itself does not induce or inhibit the cytochrome P-450 drug metabolizing enzyme system and can be used in combination with benzodiazepines, neuroleptics and anti-ulcer drugs.

Keep in a dark place and sealed. The validity period is tentatively three years.

100ml: Granisetron 3mg and glucose 5g

Heilongjiang Yudi Pharmaceutical Co., Ltd.

• Founded in:

  2022-08-25

• Address:

  Building 013, Peide Town, Mishan City, Jixi City, Heilongjiang Province (declaration commitment)

• Tax NO.:

  91230382MABY9MBL9N

• Registered Funds:

  220 million yuan

• Email:

  Log in to view